Allergan marks beginning of Botox® 30th anniversary celebrations

The close of 2019 saw global pharmaceutical company Allergan begin its celebrations to mark the 30th anniversary of Botox® by ringing the opening bell at the New York Stock Exchange.

Over the last three decades more than 100 million vials of Botox® and Botox® Cosmetic have been manufactured worldwide. With two additional US Food and Drug Administration approvals being given in 2019, Botox® now has 14 approved therapeutic and aesthetic indications combined. 

"This incredible milestone underscores our constant focus on innovation and motivates us to further build on our 30 years of research and development efforts for Botox^®," said Mitchell Brin, MD, senior vice president global drug development and chief scientific officer, Botox® and Neurotoxins. "For three decades, our team has been dedicated to manufacturing and delivering Botox® from an unparalleled state-of-the-art facility, abiding to the strictest quality and safety standards. As we now look forward to the next 30 years and beyond, we maintain our commitment to serve patients worldwide across a wide spectrum of diseases and clinical needs."

In 2019, Allergan received FDA approval for Botox^® to treat paediatric patients with lower limb spasticity.